Latest News

Today we celebrate the success of our colleague, and Scientific Advisory Board member, Dr Samson Fung. Dr Fung was recently co-authored in a publication by JCO Precision Oncology released on 4th November, 2022, for his work as a study director in a Ph I FIH clinical study in patients with metastatic breast cancer. Believed to […]

Amyotrophic lateral sclerosis (ALS) is a rare, progressive neurodegenerative disease that affects the motor neurons controlling voluntary muscle movement. The onset is usually quite gradual, with patients noticing muscle weakness – including tripping or dropping things, in the early stages. Not all patients with ALS experience the same symptoms, and progression rate and survival time […]

We are proud to share that two of our Simbec-Orion colleagues are amongst the Welsh businesses and individuals shortlisted in the Wales STEM Awards 2022, which celebrate those making a difference to, and championing, Science, Technology, Engineering, and Maths (STEM) in Wales. The awards celebrate those leading the sector in Wales, those businesses creating an […]

We are thrilled that two of our Simbec-Orion colleagues are amongst the Welsh businesses and individuals shortlisted in the Wales STEM Awards 2022, which celebrate those making a difference to, and championing, Science, Technology, Engineering, and Maths (STEM) in Wales. The awards celebrate those leading the sector in Wales, those businesses creating an impact on […]

Simbec-Orion is honoured to have been trusted by Oxford Cannabinoid Technologies to conduct this milestone first-in-human, Phase1 clinical trial of its lead compound, OCT461201 for Postherpetic Neuralgia (PHN) & Irritable Bowel Syndrome. Chief Scientific Officer, Valentino Parravicini recently shared the excitement within OCT in reaching the clinical milestone and the significance of partnering with Simbec-Orion for […]

Simbec-Orion is delighted to share the further expansion of our Clinical Pharmacology Scientific Advisory Board (SAB), with the recent appointment of Dr Kirsty Widenbach. Compared with traditional first-into-human studies, complex early phase studies with umbrella protocols or adaptive designs can offer critical data earlier whilst reducing cost. Such trials require a CRO that is both […]

We are excited to be attending the World Orphan Drug Congress USA in Boston! The World Orphan Drug Congress brings together leading pharmaceutical and biotech companies, government and regulatory authorities, patient advocacy groups, payers, investors and solution providers. The conference is a place to meet and brainstorm ways to advance orphan drug development and improve access to life-saving […]